Casdozokitug

Phase 2Small molecule

CCoherus Oncology, Inc.

Casdozokitug is one of 30 small molecule programs targeting Hepatocellular Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hepatocellular CarcinomaActive, not recruiting

Hepatocellular CarcinomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

265 competitors in Hepatocellular Carcinoma

#DrugCompanyPhaseTrials

Ibrance

Pfizer

Preclinical

1 2

Cysteine Hydrochloride

Novartis

Preclinical

1 3

Hepsera

Doptelet

1 5

Miraclid

TTechpool Bio-Pharma Co., Ltd.

Preclinical

1 6

Vermox

WWim Janssens

Preclinical

1 7

Valemetostat

Bristol-Myers Squibb

Preclinical

1 8

Casdozokitug

CCoherus Oncology, Inc.

Phase 2

1 9

Alcohol

Astellas

Preclinical

—10

Chemotherapy Drug

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Active, not recruiting

Hepatocellular Carcinoma

NCT06679985

Clinical

Trials by Indication[1]

Hepatocellular Carcinoma1 trial

A Randomized Phase 2 Study of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma

Active, not recruiting·CCoherus Oncology, Inc.·Phase 2·NCT06679985·72 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Casdozokitug. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Casdozokitug compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Casdozokitug. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Coherus Oncology, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: CCoherus Oncology, Inc.

Casdozokitug

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Hepatocellular Carcinoma1 trial

References

Drug Info

Quick Facts

Related News